The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Surface Engineering of Liposomes for Stealth Behavior
Open accessAbstract
Liposomes are used as a delivery vehicle for drug molecules and imaging agents. The major impetus in their biomedical applications comes from the ability to prolong their circulation half-life after administration. Conventional liposomes are easily recognized by the mononuclear phagocyte system and are rapidly cleared from the blood stream. Modification of the liposomal surface with hydrophilic polymers delays the elimination process by endowing them with stealth properties. In recent times, the development of various materials for surface engineering of liposomes and other nanomaterials has made remarkable progress. Poly(ethylene glycol)-linked phospholipids (PEG-PLs) are the best representatives of such materials. Although PEG-PLs have served the formulation scientists amazingly well, closer scrutiny has uncovered a few shortcomings, especially pertaining to immunogenicity and pharmaceutical characteristics (drug loading, targeting, etc.) of PEG. On the other hand, researchers have also begun questioning the biological behavior of the phospholipid portion in PEG-PLs. Consequently, stealth lipopolymers consisting of non-phospholipids and PEG-alternatives are being developed. These novel lipopolymers offer the potential advantages of structural versatility, reduced complement activation, greater stability, flexible handling and storage procedures and low cost. In this article, we review the materials available as alternatives to PEG and PEG-lipopolymers for effective surface modification of liposomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · cited 1×
“clinical usage [26].”
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533 · cited 2×
“Besides immunologic reactions, long-term toxicity studies of PEGylated preparations are limited in number, and the majority of them seem to ignore the biological fate of the PEG after the disintegration of PEGylated liposomes [100–102].”
BackgroundLong-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Conformations of Polymers Attached to an Interface
de Gennes, P. G. (1980) · Macromolecules · doi:10.1021/ma60077a009 · Cited by 2,344
PEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,339
Jiang, S., & Cao, Z. (2010) · Advanced Materials · doi:10.1002/adma.200901407 · Cited by 2,027
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,561
Protein—surface interactions in the presence of polyethylene oxide
Jeon, S. I., Lee, J. H., Andrade, J. D., & De Gennes, P. G. (1991) · Journal of Colloid and Interface Science · doi:10.1016/0021-9797(91)90043-8 · Cited by 1,523
Allen, T. M., Hansen, C., Martin, F., Redemann, C., & Yau-Young, A. (1991) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(91)90246-5 · Cited by 1,391
Cited by
Controlled drug release from pharmaceutical nanocarriers
Lee, J. H., & Yeo, Y. (2015) · Chemical Engineering Science · doi:10.1016/j.ces.2014.08.046 · Cited by 628
Zylberberg, C., & Matosevic, S. (2016) · Drug Delivery · doi:10.1080/10717544.2016.1177136 · Cited by 627
Liposomes as biocompatible and smart delivery systems – the current state
Dymek, M., & Sikora, E. (2022) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2022.102757 · Cited by 392
Therapeutic strategies to combat antibiotic resistance
Brooks, B. D., & Brooks, A. E. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.027 · Cited by 367
Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies
Marques, A. C., Costa, P. J., Velho, S., & Amaral, M. H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.035 · Cited by 349
RNA interference-based therapy and its delivery systems
Chen, X., Mangala, L. S., Rodriguez-Aguayo, C., Kong, X., Lopez-Berestein, G., & Sood, A. K. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9717-6 · Cited by 329
Antibiotics, Resistome and Resistance Mechanisms: A Bacterial Perspective
Sultan, I., Rahman, S., Jan, A. T., Siddiqui, M. T., Mondal, A. H., & Haq, Q. M. R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02066 · Cited by 320
Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery
Almeida, B., Nag, O. K., Rogers, K. E., & Delehanty, J. B. (2020) · Molecules · doi:10.3390/molecules25235672 · Cited by 298
Self-citationNonspecific Binding—Fundamental Concepts and Consequences for Biosensing Applications
Frutiger, A., Tanno, A., Hwu, S., Tiefenauer, R. F., Vörös, J., & Nakatsuka, N. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00044 · Cited by 278
Cell membrane coated nanocarriers - an efficient biomimetic platform for targeted therapy
Dash, P., Piras, A. M., & Dash, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.012 · Cited by 260
Exosome-Based Drug Delivery: Translation from Bench to Clinic
Koh, H. B., Kim, H. J., Kang, S.-W., & Yoo, T.-H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082042 · Cited by 259
Durfee, P. N., Lin, Y.-S., Dunphy, D. R., Muñiz, A. J., Butler, K. S., Humphrey, K. R., Lokke, A. J., Agola, J. O., Chou, S. S., Chen, I.-M., et al. (2016) · ACS Nano · doi:10.1021/acsnano.6b02819 · Cited by 219
Lakkadwala, S., dos Santos Rodrigues, B., Sun, C., & Singh, J. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.033 · Cited by 160
Enhanced immunocompatibility of ligand-targeted liposomes by attenuating natural IgM absorption
Guan, J., Shen, Q., Zhang, Z., Jiang, Z., Yang, Y., Lou, M., Qian, J., Lu, W., & Zhan, C. (2018) · Nature Communications · doi:10.1038/s41467-018-05384-1 · Cited by 152
dos Santos Rodrigues, B., Oue, H., Banerjee, A., Kanekiyo, T., & Singh, J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.043 · Cited by 116
Guo, Y., Wan, Z., Zhao, P., Wei, M., Liu, Y., Bu, T., Sun, W., Li, Z., & Yuan, L. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01145-3 · Cited by 60
Synergistic vesicle-vector systems for targeted delivery
Marquez, C. A., Oh, C.-I., Ahn, G., Shin, W.-R., Kim, Y.-H., & Ahn, J.-Y. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02275-6 · Cited by 37
Short Peptide-Mediated Brain-Targeted Drug Delivery with Enhanced Immunocompatibility
Guan, J., Jiang, Z., Wang, M., Liu, Y., Liu, J., Yang, Y., Ding, T., Lu, W., Gao, C., Qian, J., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01216 · Cited by 34
Metadata
- Authors
- Nag, O., & Awasthi, V.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2013-10-25
- Volume
- 5
- Issue
- 4
- Pages
- 542-569
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W1990053723
- Cited by
- 322
- References
- 157
- FWCI
- 6.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.